BioIncept LLC Information
Contact top employees from
BioIncept LLC
Summary
BioIncept LLC is a private company that has been in the industry for 25 years. The company currently specializes in the Wine and Spirits, Biotechnology areas. The position of the CEO is occupied by Brian K. Foster. Its headquarters is located at New York, New York, USA. The number of employees ranges from 25 to 100. The annual revenue of BioIncept LLC varies between 5.0M and 25M. Total funding of the company - $15.6M. To connect with BioIncept LLC employee register on SignalHire.
Organization Website | bioincept.com |
Social Links |  |
Phone Number | 203-222-7386 |
Industries | |
Headquarters Location | Cherry Hill, New Jersey, US |
Employees Size | 1-10 employees |
SIC Code | 8000, 5047 |
DMA Code | New York Metropolitan Area |
Founded | 2001 |
Estimated Annual Revenue | $5.0M - 25M |
Operating Status | Independent Company |
Competitors
Founded | Type | Employees | Revenue | Funding | |
|---|---|---|---|---|---|
| 1997 | Public Company | 100 - 250 | 21.6M | $679.3M | |
| 1979 | Public Company | 250 - 500 | 6.5M | $296.4M | |
| 2013 | Public Company | 100 - 250 | 89.2M | $204.8M | |
| 2000 | Public Company | 25 - 100 | 25.9M | $322.5M |
Employees Turnover 4 quarter 2025
Length of Employment
Employee tenure at BioIncept LLC shows a diverse range of experience levels:
25% for 3–4 years25% for 8–10 years50% have over 11 years of service at BioIncept LLCContact top employees from
BioIncept LLC
Dennis Spink
Board Director
Amy Carter
Business Manager
Similar Companies
FAQ
BioIncept LLC operates in the Alcohol industries. More details can be found on the official website: bioincept.com.
The headquarters of BioIncept LLC are located in Cherry Hill, United States.
The current CEO of BioIncept LLC is Brian K. Foster
You can contact BioIncept LLC by phone at 203-222-7386.
BioIncept LLC currently employs 1-10 people.
BioIncept LLC's revenue is approximately 12.3M.
Well-known competitors of BioIncept LLC include ChemoCentryx, INOVIO Pharmaceuticals, Inc., Jounce Therapeutics, Inc. and Merrimack.
